Mirum Pharmaceuticals ((MIRM)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Mirum Pharmaceuticals is conducting a Phase 3 study titled ‘Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND).’ The study aims to assess the safety and efficacy of maralixibat, an investigational treatment, in both pediatric and adult patients suffering from cholestatic liver disease with pruritus, who have not responded to other treatments. This study is significant as it targets a patient group with limited therapeutic options.
The intervention being tested is maralixibat, an oral solution designed to alleviate pruritus in patients with cholestatic liver disease. The study involves administering maralixibat to participants over a 39-week period, with a placebo group receiving a matched solution before switching to maralixibat.
This randomized, double-blind, placebo-controlled study employs a parallel intervention model with quadruple masking. The primary purpose is treatment, ensuring unbiased results in evaluating maralixibat’s effectiveness.
The study began on October 14, 2024, with the last update submitted on July 16, 2025. These dates are crucial as they indicate the study’s progress and ongoing recruitment status, which is essential for tracking future developments.
The outcome of this study could significantly influence Mirum Pharmaceuticals’ market position, potentially boosting investor confidence and stock performance if results are favorable. The study’s progress is also relevant in the context of the competitive landscape of treatments for liver-related pruritus.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.